Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.6c00256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Nghia Trong Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Te…. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Radioisotopes, Integrins, Lutetium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, S?chsische Aufbaubank, TRIMT GmbH.
Abstract (Originalsprache)
Theranostic radiopharmaceuticals exploit the same molecular target for diagnosis and therapy. Among emerging pan-cancer targets, αvβ6-integrin is highly expressed on various malignant cell types and can be imaged clinically with Ga-68-Trivehexin. However, therapeutic αvβ6-integrin-directed radioligands remain scarce. Here, Lu-177-labeled multimerics of the cyclic nonapeptides Tyr2, sequence c(YRGDLAYp(NMe)K), were constructed using the tetrafunctional chelator DOTPI by means of CuAAC-based and evaluated as αvβ6-integrin-targeted radiotherapeutics. PEG linkers of increasing length (PEG0, PEG3, PEG7, PEG11) were introduced between the chelator and peptides to modulate pharmacokinetics and cellular processing. The Lu-177-labeled conjugates displayed comparable polarity (log D7.4 ≈ -2) and αvβ6-integrin affinities determined by ELISA (IC50 ∼ 0.2-0.5 nM), indicating minimal effects of PEG length on in vitro parameters. In αvβ6-positive H2009 cells, PEG linkers markedly enhanced and prolonged receptor-mediated uptake and internalization, consistent with improved multivalent engagement. In H2009 xenograft mice, PEG linkers reduced early blood-pool activity and increased tumor uptake at 24 h, while gelofusine (4% succinylated gelatin in Ringer's acetate) efficiently mitigated the elevated renal retention (up to 92% reduction). Performance gains plateaued beyond PEG7, identifying the PEG7 trimer (P7) as the preferred lead due to favorable tumor uptake/retention. P7 exhibited high selectivity (65- to 671-fold) over other integrin subtypes, αvβ6-integrin-dependent radiotoxicity to tumor cells, and sustained tumor retention for up to 6 days according to μSPECT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Technical University Munich, Munich 81675, Germany.
- TRIMT GmbH, Carl-Eschebach-Str. 7, Radeberg 01454, Germany.
- Institute of Pathology, School of Medicine, Technical University Munich, Trogerstr. 18, Munich 81675, Germany.
ORCID-Profile: Johannes Notni
Förderung
- European Commission
- S?chsische Aufbaubank
- TRIMT GmbH
Zitieren
APA
Nguyen, N. T., Rheinfrank, T., Stangl, S., Reissig, F., Kossatz, S., & Notni, J. (2026). Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00256
Vancouver
Nguyen NT, Rheinfrank T, Stangl S, Reissig F, Kossatz S, Notni J. Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00256
BibTeX
@article{Nguyen2026,
author = {Nguyen, Nghia Trong and Rheinfrank, Tim and Stangl, Stefan and Reissig, Falco and Kossatz, Susanne and Notni, Johannes},
title = {Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00256}
}
EUVIMED